Integra launches Allograft Cancellous Sponge
This article was originally published in Clinica
Integra LifeSciences has launched its Integra Allograft Cancellous Sponge, a compressible bone graft composed of 100% cancellous bone, in the US. The graft is used to replace damaged bone that has been surgically removed from the spine, extremities and pelvis, because of trauma, for example. Bone grafts such as Integra's provide a scaffold for the growth of new bone. The device can absorb fluids like saline, blood or bone marrow aspirate, and can conform to a variety of spaces and defects allowing surgical flexibility. The Integra distributor network will sell the sponge in the US. The US market size for bone graft substitutes in orthopaedic spinal procedures is estimated at $560m, excluding growth factors, stem cell therapies, and machined bone, the Plainsboro, New Jersey firm says.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.